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Skeletal muscle atrophy is a result of an imbalance in protein synthesis and
protein degradation. It is a part of the normal aging process, but also may occur in
response to several stimuli including disease, injury, and disuse. Currently there is no
truly effective pharmacological treatment for atrophy. The best treatment is a healthy
diet and exercise, however, sick and aging individuals are not always capable of
participating in the appropriate activity. Therefore, exploration of the mechanisms
contributing to atrophy is essential because this may lead to discovery of an effective
therapeutic target. The ether-a-go-go related gene (Erg1a) K+ channel has been shown
to contribute to atrophy by up-regulating ubiquitin proteasome proteolysis in mice.
Recent studies have shown that it also increases the intracellular calcium concentration
in skeletal muscle. The aim of this work is to investigate the modulation of the increased
intracellular [Ca2+] and its potential downstream effects on calpain activity. To do this,
we overexpressed human ERG1A (HERG1A) in a mouse myoblast cell line (C2C12
cells). Looking for the source of increased calcium levels we investigated the skeletal
muscle specific, voltage gated calcium channel (CAV1.1). We were able to discover that
i

there is a significant 2.3 fold increase in Cav1.1 gene expression. Conversely, upon
immunoblotting the protein abundance of Cav1.1 had no detectable change. Calpains,
which are calcium activated cysteine proteases take part in the degradation of
myofilaments when they are activated via calcium. The activity of these calpains were
shown to have a 25.7% higher level of activity in response to HERG expression. The
change in calpain activity may be attributable to increased calpain transcription,
translation or changes in their inhibitor, calpastatin. When gene expression was
analyzed for calpains and calpastatin, no significant change was observed. However,
after analysis of protein abundance a decrease was found in calpains 2 and 3, along
with calpastatin, suggesting that HERG1A may indeed be effecting calpain abundance.
With our data we were able to conclude that the increase in intracellular [Ca2+] due to
the presence of HERG1A is not due to Cav1.1. We were able to report that an increase
in calpain activity occurred in response to HERG1A within C2C12 cells, however this
was not due to changes in gene expression, but their protein abundance appears to
decrease in response to HERG1A.
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CHAPTER 1
INTRODUCTION

Skeletal muscle comprises approximately 40% of the total human body weight
and contains 50-75% of all bodily proteins. It has multiple functions within the human
body. It converts chemical energy into mechanical energy that can then be used to
support body posture and generate force and movement for everyday activities [1]. It
contributes to basal energy metabolism and maintains the core body temperature while
consuming the majority of oxygen and fuel used in the body. It also functions to store
substrates for both energy production and cell growth (e.g., carbohydrates and amino
acids) [1] . Thus, an adequate amount of skeletal muscle tissue is necessary for good
health and a reduction in skeletal muscle tissue will compromise health, potentially
inhibiting the body’s ability to respond to illness and stress [1] . Growth of skeletal
muscle occurs by the process of myogenesis, in which myoblasts fuse together to form
multinucleated myofibers. This growth process is maintained by a continuous,
fluctuating balance between protein degradation and protein synthesis; however, when
the rate of degradation increases or the rate of protein synthesis decreases muscle
mass can be lost in a process known as atrophy. Skeletal muscle atrophy is defined as
a decrease (equal to or greater than 5%) in muscle mass as a result of cellular
shrinkage [2]. Indeed, certain external stimuli can interfere with the correct balance
between protein synthesis and degradation and cause fully formed muscle cells to
degrade at an accelerated rate. Muscle disuse, denervation, starvation, disease (e.g.,
diabetes and cancer), loss of neural input, along with the normal aging process are a
1

few of the events that can induce muscle atrophy [3]. Treatments for skeletal muscle
atrophy currently under study include administration of pharmaceuticals such as growth
factors [4], beta-agonists [5], inhibitors of proteolysis [6, 7], stimulators of protein
synthesis [8] and myostatin inhibitors [9-11]; however, these are not adequately
effective. Thus, further investigation into the mechanisms resulting in atrophy is needed
to reveal new and improved targets for therapy.
The contractile subunit of skeletal muscle is called the sarcomere (Figure 1).
The sarcomere is primarily composed of myofilaments, namely actin and myosin (thin
and thick filaments, respectively), which function to produce muscle contraction. Other
proteins often referred to as “anchoring” proteins assist in stabilizing the sarcomere,
these include titin, nebulin, α- actinin, and desmin [1]. Titin is an elastic protein that
attaches to the Z disc and helps align and stabilize myosin. Nebulin is often referred to
as actin’s “ruler” because it stabilizes actin, being approximately the same length as this
filament. The α-actinin protein is found on the Z disc and serves as an anchoring point
for actin to this structure. Lastly, desmin is a protein that lies along the Z disc and
connects this structure with the sarcolemma and extracellular matrix (Figure 1) [1].
Contraction occurs when the myosin head “pulls” itself along the actin filament causing
interdigitation of the actin and myosin filaments (Figure 1); proteins found along the
actin filament known as troponin and tropomyosin produce this activity. Tropomyosin
lies on the actin protein and blocks the binding sites on actin for the myosin heavy chain
head. Troponin lies on top of the tropomyosin. Once Ca2+ is released from the
sarcoplasmic reticulum in response to an action potential, troponin binds calcium and
this binding changes the conformation of tropomyosin to expose the myosin head
2

binding sites on the actin (Figure 2) [1]. Myosin may then bind actin repeatedly like a
ratchet, causing the interdigitating of the filaments and thus contraction. The
degradation of these thin and thick contractile filaments is the primary cause of skeletal
muscle atrophy; thus, reduction of actin and myosin proteins will lead to reduced muscle
mass and strength.
There are three primary proteolytic systems that can contribute to atrophy when
active: the ubiquitin proteasome pathway (UPP), cathepsins, and calpains. The UPP
has been reported to be the primary pathway that is responsible for the protein
degradation that produces skeletal muscle atrophy. It consists of a series of enzymes
which activate ubiquitin and attach it to target proteins, and a proteasome unit which
degrades the ubiquitinated proteins [3]. Cathepsins, which are a type of cysteine
protease, are secreted into the cytosol from the lysosome and initiate the lysosomal
pathway to assist in the degradation of proteins [12]. Lastly, calpains, which are the
focus of our study, are calcium activated cysteine proteases that are active during
atrophic conditions. Specifically, we have focused on the conventional calpains, 1 and
2, along with the skeletal muscle specific, calpain 3. Finally, we have also focused on
calpastatin, which is a native protein inhibitor of the conventional calpains [13].
Calpains are detected throughout the body and participate in various processes,
including embryonic development and cell function, intracellular signaling, regulation of
gene expression, modulation of the cell cycle, and even apoptosis [14]. Increases in
calcium increase calpain activity. In skeletal muscle, calpains have been shown to act
upon anchoring proteins (e.g., titin, nebulin, and desmin), which attach the sarcomere’s
myofilaments to the Z-disc [15]. The cleavage of these proteins subsequently releases
3

α-actinin and thus results in the release of the actin thin filament from the myofibril.
Thus, the activation of calpains assists in the degradation of myofibers and the release
of their constituent myofilaments (actin and myosin), allowing these proteins to be
ubiquinated and consequently degraded by the proteasome [15, 16]. Calpains are
additionally known to aid in modulation of signaling pathways. For example, the Akt
pathway is known to modulate the balance of protein synthesis and degradation and
studies have shown that increased calpain activity will decrease the activity of Akt. The
decrease in Akt allows for a decrease in mTOR kinase activity, which contributes to upregulated protein synthesis. Decreased Akt activity also leads to an increase in the
abundances of proteins FoxO1, 3 and GSK-3ß which, when present, lead to protein
degradation. Thus, increased calpain activity results in a decrease in protein synthesis
and an increase in protein degradation (Figure 3) [16]. The role of calpains does not end
there. They have also been shown to degrade tropomyosin and troponin proteins,
however, at a much slower rate than anchoring proteins [15]. Combined with the
cleavage of titin, this degradation allows the removal of the thick filament from the
myofibril. It is important to note that calpains do not cleave proteins into amino acids;
rather they cleave specific proteins into large fragments [7]. Thus, calpain activity allows
for the disassembly of the sarcomere, allowing actin and myosin to become accessible
for ubiquitination and subsequent degradation by the proteasome [15-17].
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Figure 1. Organization of proteins within a sarcomere [18].

Figure 2. When bound with calcium troponin changes conformation and shifts the
tropomyosin protein to expose myosin binding sites on actin, allowing the myosin head
to pull itself along the actin filament [19].

5

Figure 3. Some consequences of calpain activation.
The ERG1 voltage-gated potassium channel alpha subunit is a product of the
ERG1 (ether-a-go-go related gene) gene, which is located on chromosome 7 in humans
and spans approximately 33 kb. The gene encodes 15 exons and has three alternative
transcription start sites along with two alternative termination sites, which allows for five
unique transcripts (Figure 4) [20]. The ERG1a protein has six membrane-spanning
domains, a conserved pore domain, and an N-terminus with numerous potential
signaling domains such as a cyclic nucleotide-binding domain and a Per-Arnt-Sim
(PAS) domain (Figure 5A) [20, 21]. The alternative splice variant ERG1b subunit is
essentially identical to the 1a variant except that is has a truncated N-terminus. The 1b
is considered to be a cardiac specific isoform [20, 21], although there are reports of its
6

detection in brain and cancer cells [22, 23]. The main difference between the 1b variant
and others is that the ERG1b lacks the first 373 amino acids found in 1a, and rather
contains its own unique 36 amino acid sequence at the NH2 terminus [20, 21]. The
ERG1 channel is a heteromultimer composed of four alpha subunits. Interestingly, it has
been shown that the cardiac ERG1 channel is composed of two ERG1a proteins and
two ERG1b proteins [21] while the skeletal muscle channel is solely composed of the
ERG1a variant which will be the focus of this study [24].

Figure 4. Genomic structure of chromosome 7 including the location of the ERG
gene (top, red line). The 5 transcript variants of ERG result from alternative transcription
start and termination sites (bottom). Blue boxes indicate exon-coding regions, red areas
signify 5’ and 3’ UTRs, and blue arrows represent introns [20].
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Figure 5. (A) Linear sequence of the HERG1A channel with domains color-coded.
Dotted lines represent exon-exon junctions while arrows represent transcription start
sites. (B) Extracellular view of the HERG1A channel (left) and intracellular view (right)
color-coded to match the linear sequence in A. (C) Topology of two HERG1A subunits
once again color-coded to match panels A and B [20].
ERG1 is well conserved across many mammalian tissues including brain and
heart, but had not been reported in skeletal muscle until the report from the Pond and
Hannon labs [24]. Within heart tissue the ERG1 potassium channel has been shown to
conduct the IKr current and be partially responsible for the repolarization of the cardiac
action potential [20, 21, 25]. Indeed, mutations found in human ERG1 (HERG1) can
produce a form of long QT syndrome, (LQT2) an arrhythmia brought about by prolonged
repolarization of the cardiac action potential that can lead to sudden cardiac death.
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In 2006, the Pond and Hannon labs demonstrated that ERG1a expression and
protein abundance increases in the skeletal muscle of mice in response to hind limb
suspension and with tumor expression. Indeed, when ectopically expressed in the
skeletal muscle of weight bearing mice, mouse ERG1a (MERG1A) was shown to induce
atrophy. Further, when ERG1a was either pharmacologically or genetically blocked, the
skeletal muscle atrophy normally caused by hind limb suspension was inhibited [24].
Specifically, they reported that the MERG1A protein increased in Gastrocnemius
muscles after 4 days of hind limb suspension (i.e., unweighting), prior to the onset of
significant atrophy, and was still up-regulated after 7 days of hind limb suspension when
significant atrophy was noted. They also reported that the MERG1A channel was upregulated in the skeletal muscle of cachectic mice. They further demonstrated that
genetic and pharmacologic attenuation of MERG1A channel activity prevented atrophy
in suspended mice and that expression of Merg1a was found to induce a decrease in
cross sectional area of muscle fibers in weight bearing mice. Most importantly their
findings concluded that the MERG1A channel participates in the initiation of atrophy by
signaling for an increase in UPP activity [24].
More than half of the skeletal muscle wasting that occurs in response to
immobilization has been shown to be caused by the UPP pathway (Figure 6).
Specifically, this pathway is composed of three main enzymes (E1, E2, and E3) and a
proteolytic unit called the proteasome. E1 is an ubiquitin-activating enzyme which
allows ubiquitin to be attached to ATP and then passed along to E2, which is known as
the ubiquitin-conjugating enzyme. E3 ligases are the final enzymes and these transfer
ubiquitin to the targeted protein substrate by ligation. Polyubiquitination of a substrate
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makes it a target for degradation by the proteasome [2, 15, 26]. MURF1 and
Mafbx/ATROGIN1 are two muscle specific E3 ligases and are known to be up regulated
in atrophic muscle [3]. ERG1a has since been shown to modulate the expression of the
E3 ligase MURF1, however, it does not modulate expression of the E3 ligase
Mafbx/ATROGIN1. This suggests that ERG1a participates in the process of skeletal
muscle atrophy at least partially through modulation of the ubiquitin proteasome
pathway [25].

Figure 6. The ubiquitin proteasome pathway [2].
Calcium has multiple roles in skeletal muscle. One of the primary roles is
initiation of excitation-contraction coupling (ECC) which requires M concentrations of
calcium ions; however, at nM concentrations calcium also acts as a second messenger
in cell signaling systems, modulating the expression of genes needed for growth and
differentiation [27-30]. Two different types of calcium transients have been identified in
10

skeletal muscle, a fast and a slow component. The initial fast calcium release is linked
to contraction while the second slow calcium release shows a response to
depolarization that is unrelated to ECC. This slow release of calcium in response to
depolarization results from an increase in inositol 1,4,5-triphosphate (IP3) [27]. IP3 binds
to its receptor (IP3R) and leads to calcium release into the cytosol from the sarcoplasmic
reticulum (SR). This calcium is then taken back into the SR via SERCA. The activation
of the IP3R consequently leads to the slow calcium component [27, 31]. The slow
calcium transient brought on by depolarization and the consequent increase in IP 3 have
been linked to activation of early genes in skeletal muscle, specifically c-fos, c-jun, egr-1
along with P-ERK (MAPK/ERK pathway) and the cAMP response element-binding
protein (P-CREB) [29].
Human ERG1A (HERG1A) has been shown to increase the basal intracellular
calcium concentration ([Ca2+]i) of SKBr3 breast cancer cells [32]. Indeed the Pond and
Hockerman labs have also shown that HERG1A expression will increase the basal
[Ca2+]i of C2C12 myotubes as well as produce a transient increase in the [Ca2+]i of
myotubes in response to depolarization (Figure 7, unpublished data, Pratt, Hockerman,
Pond). However, the mechanism by which the HERG1A channel has this effect is not
known. Indeed, we hypothesized that HERG1A expression would increase calpain
activity in C2C12 myotubes as a result of the increased calcium concentration. Here,
we perform studies designed to explore this hypothesis and the possible consequences
of increased calcium activity in the C2C12 myotubes.
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Figure 7. Fura2 dye experiments (340/380nm ratio) reveals a 34% increase in basal
intracellular calcium levels ([Ca2+]i) in HERG1A transduced cells as opposed to GFP
transduced control cells. (p<0.0001; n=90 control, n=87 HERG1A). Bars represent the
mean while error bars represent the standard error from mean (mean ± SEM)
(unpublished data, Pratt, Hockerman, and Pond).
The ultimate goal of the Pond lab is to explore the mechanism by which
HERG1A affects skeletal muscle atrophy. Here, our focus will be on identifying the
source of increased [Ca2+]i and its downstream effects on protein degradation,
specifically calpain enzymes and the calpain inhibitor calpastatin (i.e., their activity,
abundance, etc.). We hypothesize that the increase in [Ca2+]i is not due to an increase
in voltage gated calcium channels. Further, we hypothesize that calpain activity will
increase as a result of the increase in [Ca2+]i. Using an in vitro model, we have
overexpressed HERG1A in C2C12 myotubes and produced a decrease in their area
12

thus simulating atrophy. We observed that in response to HERG1A overexpression,
myotubes have an increase in voltage gated calcium channel 1.1 (Cav1.1) mRNA,
however, at the protein level no difference was observed. This suggests that there is an
increase in transcription but it is not being translated into a change in protein abundance
– at least not a detectable change. Thus, it is not likely that the increase in calcium is a
result of increased Cav1.1 channels. We have also been able to show an increase in
calpain activity in response to 48 hour HERG transduction. The detected increase in
calpain activity was shown not to be a result of an increase in transcription of calpains 1,
2, nor 3. Lastly, we investigated the amount of calpastatin present in response to
HERG1A, results showed that calpastatin transcription is not affected by the presence
of HERG1A. When immunoblots were performed no change in protein abundance was
found in calpain 1. Interestingly, immunoblots for calpains 2 and 3 and calpastatin
revealed that there was a statistically significant increase in their protein abundance
(40.69%, 38.9%, and 37.7%, respectively).
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CHAPTER 2
METHODS AND MATERIALS
Antibodies
Anti-Cav1.1 (extracellular) (Alomone labs, Jerusalem, Israel, Cat #: ACC-314)
Calpain-1 Polyclonal Antibody (BioVision, Milpitas, CA, Cat #: 3189-30T)
Calpain-2 Polyclonal Antibody (BioVision, Milpitas, CA, Cat #: 3372-30T)
Calpain-3 Polyclonal Antibody (ABclonal, Woburn, MA, Cat #: A11995)
Calpastatin Polyclonal Antibody (ABclonal, Woburn, MA, Cat #: A7634)
Cell Culture
C2C12 myoblasts were grown in Dulbecco’s Modification of Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and maintained in a
humidified incubator with 10% CO2 at 37⁰C. To differentiate myoblasts into myotubes,
cells were grown in DMEM supplemented with 10% FBS to ~85% confluence. The FBS
medium was then removed from the cells and replaced with DMEM medium
supplemented with 2% heat inactivated horse serum to initiate differentiation. Cells were
incubated for 4 days in order to terminally differentiate into myotubes.
Collagen Coating of TC Plates
Due to an observed tendency for mature myotubes to release from the bottom of
cell culture dishes, plates were treated with rat collagen prior to being seeded with cells.
To coat the plates, 1mL of 1M acetic acid was added to 9mL of deionized water (or the
14

proportionate amount) and mixed to achieve a final concentration of 0.1M acetic acid.
This solution was mixed with rat collagen to produce a final concentration of 1 mg/mL
collagen. The plates were then coated with enough rat collagen solution to cover the
bottom of the plate and these were then incubated for 1 hour at 37⁰C. After an hour, the
liquid was removed and the plates were washed with PBS twice. Plates were left under
UV light overnight and then covered with parafilm and stored in the refrigerator until
needed. When the plates were required they were incubated at 37⁰C for 10 minutes
before cells were plated.
Viral Transduction of Cells
At terminal differentiation (4 days post addition of horse serum medium), the
myotubes were treated with 200 MOI virus (from a 2x1010pfu [plaque-forming units]
stock suspension of viral particles) as was determined previously to produce HERG1A
protein after 48 hours. The amount of virus needed was calculated by the equation:
𝑋 ∙ 200 = 2 × 1010 𝑝𝑓𝑢 ∙ 𝑌
Where 𝑋 is the number of cells and 𝑌 is the amount of virus in milliliters which was then
converted to microliters. One set of cells was treated with control GFP adeno-virus
(VQAd EMPTY-eGFP; ViraQuest, New Liberty, IA) while the other received adeno-viral
particles encoding the human ERG1A K+ channel (VQAd CMV Herg-GFP; ViraQuest,
New Liberty, IA). The amount of virus was then carefully pipetted into the correct
volume of DMEM supplemented with 2% horse serum needed for the amount of
plates/wells and triturated slowly. The HS medium that was present on the plates was
drawn off with a pipet and replaced with the 2% HS medium treated with virus. The cells
15

were then incubated for 48 hours and monitored via fluorescence to verify that the
transduction was successful.
RNA Isolation
For isolation of RNA cell cultures were rinsed with PBS followed by the
addition of 0.5 mL cold Trizol reagent (Life Technologies; Carlsbad, CA) for one minute.
Tissue culture plates (10 cm) with a confluent layer of C2C12 myotubes were then
scraped with a clean lab spatula and this material was collected in a 1.5 mL Eppendorf
tube. A 100 L aliquot (20% of original volume) of chloroform was then added to the
Eppendorf tube and this was vortexed for 30 seconds. The Eppendorf tubes were then
centrifuged for 15 minutes at 12,000 rpm at 4°C. Following centrifugation, the top
aqueous layer in the Eppendorf tube (~250 L) was removed and placed into a clean
1.5 mL Eppendorf tube. A 250 L aliquot of isopropanol was added to the aqueous
solution, vortexed and incubated at room temperature for 10 minutes. The Eppendorf
tubes were once again centrifuged for 10 minutes at 12,000 rpm at 4°C. The
supernatant was decanted and 0.8 ml of 70% ethanol was pipetted onto the resultant
pellet followed by centrifugation for 5 minutes at 12,000 rpm at 4°C. The supernatant
was again decanted and the excess ethanol was carefully suctioned off and the pellet
was allowed to air dry for 10 minutes. The pellet was then dissolved in 15 L of DEPC
treated water and incubated at 57°C for 10 minutes and finally vortexed briefly to
precipitate all liquid. The RNA was then measured by UV spectrophotometry using a
NanoDrop (NanoDrop ND-1000 spectrophotometer, Nanodrop Technologies, Thermo
Fischer, Wilmington, DE).
16

DNase Digestion
The GOScript™ Reverse Transcription System Kit (Promega; Madison,
WI) was used to degrade genomic DNA in the RNA samples using manufacturer’s
instructions and reagents provided in the kit. Briefly, a volume containing 3.5 g of
isolated RNA was brought to 8 L with DEPC treated water. A 1 L aliquot of 10X RQ1
Reaction buffer and 1 L of RNase free DNase were added to the RNA and water. The
reagents were then incubated in a thermocycler at 37°C for 30 minutes to degrade DNA
and then the samples were incubated at 65°C for 10 minutes to denature the DNase
enzyme. A 2 L aliquot of 50 μM oligo(dT) was added to each sample and incubated at
70°C for 5 minutes, after which the samples were chilled on ice for 5 minutes. The
sample tubes were then centrifuged lightly to collect the condensate.
cDNA synthesis
For the cDNA synthesis reaction, a reaction mixture was made with the following
components per sample: 6 L 5X GoScript RT buffer; 3.6 L 25mM MgCl2; 3 L 0.1 M
DTT;1 L 10 mM dNTPs; 2.9 L nuclease free water; and 1.5 L GoScript reverse
transcriptase. An aliquot of this reaction mixture (18 L) was placed into an appropriate
RNase- and DNase-free microtube along with 2 L of each sample. Samples were
placed in a thermocycler to incubate at 25°C for 5 minutes, 42°C for 1 hour, and 70°C
for 15 minutes. Once synthesis was complete, the cDNA samples were stored at -20°C
(final volume = 30 L).

17

Primer Design
Primers were designed using the NCBI Primer – BLAST program and DNA
sequences downloaded from NCBI except where noted. The criteria used to design
primers were as follows: amplicon length of 50 – 210 base pairs, primer length of 18 –
23 nucleotides, a GC content of 35 – 65%, and a melting temperature between 57 –
67C. The following sequences were used (Table 1). All primers were obtained from
Integrated DNA Technologies (Coralville, IA).
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Table 1. Sequences of RT-PCR primers.

Primer Name (mouse)

Primer Sequence

Size

Tm

GC

5’ – 3’

(bp)

(°C)

(%)

20

59.6

55.0

20

60.3

60.0

21

57.2

52.4

20

57.0

52.4

20

57.3

55.0

20

57.4

55.0

20

55.1

50.0

21

54.8

47.6

21

56.5

47.6

24

55.0

45.8

Merg1a Forward

Amplicon
Size (bp)

145

cctcgacaccatcatccgca

Merg1a Reverse

aggaaatcgcaggtgcaggg

18S Subunit Forward

101

cgccgctagaggtgaaattct

18S Subunit Reverse
agaacgaaagtcggaggttc

Cav1.1 Forward

88

gtcccaccaacaagatccgt

Cav1.1 Reverse

gctgagcaggatgaagagca

Cav1.1e Forward**

59

ctaatcgtcatcggcagcat

Cav1.1 embryo Reverse**

tctcatctgggtcatcgatct

Cav1.2 Forward*
atgcaagacgctatgggctat

Cav1.2 Reverse*

caggtagcctttgagatcttcttc

19

201

Cav1.3 Forward

24

55.2

41.7

116

gctggacatgctggttgttg

Cav1.3 Reverse

ttgattgctctgagaggccg

22

56.5

50.0

Calpain 1 Forward

gctaccgtttgtctagcgtc

20

58.73

55.0

Calpain 1 Reverse

taactcctctgtcatcctctggt

23

59.99

47.83

Calpain 2 Forward

ttttgtgcggtgtttggtcc

20

59.83

50.0

Calpain 2 Reverse

aactcagccacgaagcaagg

20

60.89

55.0

Calpain 3 Forward

ttcacaggaggggtgacaga

20

60.11

55.0

Calpain 3 Reverse

ttcgtgccatcgtcaatggag

21

61.01

52.38

Calpastatin Forward

gccttggatgacctgataga

20

53.8

50.0

Calpastatin Reverse

gtgcctcaaggtaggtagaa

20

53.7

50.0

*Primer sequence was obtained from B.Schlick et. al. [33].
**Primer Sequence was obtained from Nasreen Sultana et. al. [34].
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Primer Efficiency Determination
To determine the efficiency of the primer sets, a standard curve was generated
using dilutions (e.g., 1:2, 1:4, 1:8, 1:16, and 1:32) of an appropriate standard (known
plasmid or cDNA from a known tissue sample, such as heart for Cav1.2 and adrenal
glands for Cav1.3), which were assayed by real time PCR using a C1000 Thermocycler
machine (BioRad; Hercules, CA). Standards were assayed in triplicate and then
standard Ct was plotted against the log of the standard concentration. Using Microsoft
Excel (Excel 2013, Microsoft, Redmond, WA), the linearity was calculated using the Rsquare method and the slope of the line was determined and used to calculate the
efficiency of the primers: 10(-1/slope). Percentage determination was done by:

efficiency
2

×

100. The primer efficiency was considered acceptable at 95 – 105% with R-square
values of 0.985 or above for the standard curve.
Quantitative Real Time PCR (qRT-PCR)
Primer stocks for quantitative real time PCR were diluted with nuclease free
water so the final concentration of each primer was 100 M. Primers were then diluted
1:5 to a final volume of 100 l (20 M), making a working solution. Master mixes were
made so that 18 l of this mix would contain: 7 l of autoclaved water, 1 l of primer mix
(forward and reverse primers diluted in autoclaved water) final concentration of 1 M,
and 10 l of SYBR green. A master mix was made which contained primers for the gene
of interest and a second master mix was made which contained primers for a “housekeeping” gene for normalization. An 18 l aliquot of the each master mix was loaded
into wells of a 96 well plate (Thermo Scientific, Waltham, MA) in triplicate and a 2 l
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aliquot of each cDNA sample was added to the triplicate wells, with the exception of a
single triplicate set of wells which received a 2 L aliquot of non-template control (i.e., a
sample which had undergone all steps of the process without any RNA) per master mix.
An Applied Biosystems 7300 Real Time PCR machine was used for all qPCR work with
HERG/Merg to determine Ct values (Applied Biosystems; Foster City, CA). For all other
qPCR data a BioRad CFX96 Real Time System was used to determine Ct values
(BioRad; Hercules, CA). To normalize the data, the average Ct values for the target
gene were compared to that of the house-keeping18S rRNA (18S). The average Ct of
each triplicate was taken for both the target gene and the reference 18S gene. The fold
change was then determined via the 2−∆∆Ct (Livak) method (Bio Rad Laboratories, RealTime PCR Applications Guide, 2006) and an average Ct of each triplicate first taken
(Ct).
Ct(target) – Ct(ref) = ∆Ct, ∆Ct - ∆Ct(con, 0 hr) = ∆∆Ct, 2-∆∆Ct = normalized expression ratio.
Protein Harvest
Medium was aspirated and the plates were then rinsed gently with 30-37⁰C PBS
three times. A 0.3 ml aliquot of 10mM Tris 1mM EDTA (TE) containing 2% Triton X-100
and protease inhibitors (listed below) were then rinsed over each plate surface with an
Eppendorf tip or pipetteman while scraping the surface with the pipette tip. Plates were
then scraped with rubber policeman or a Teflon stirrer. Cells and cell debris were
aliquoted into an Eppendorf centrifuge tube and placed on ice. A 0.2 ml aliquot of TE
buffer was added to the plate and scraped over the surface as before. The solid
material was scraped into the liquid and pipetted into the Eppendorf tube and pooled
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with the earlier aliquot. The sample was then triturated with a tuberculin syringe and
23G1 needle until solid particles were broken up. The tubes were then left on ice and
placed in the refrigerator for 30 minutes to solubilize. It was then triturated a second
time with a syringe and needle for 1-2 minutes. Eppendorf tubes with material were then
centrifuged in a tabletop centrifuge for 2 minutes at 15,000 rpm. If the supernatant
appeared cloudy or large amounts of solid were present the supernatant was removed
to a second Eppendorf tube and centrifuged a second time. The aliquot was then
frozen, retaining a small amount (~20l) for protein microassay.
Protease inhibitors per 100ml of TE buffer:
500l of 100mM stock pefabloc or PMSF (in ethanol) (final = 0.5mM)
100l of 1mM (0.7 mg/ml) stock pepstatin (final = 1mM)
2.0ml of 50mM stock benzamidine (final = 1mM)
200l of 2.0mg/ml stock aprotinin (final = 4μg/ml)
1.0ml of 100mM stock Iodoacetamide (final = 1mM)
1.0ml of 100mM stock 1,10-phenanthroline (final = 1mM)
Protein Microassay
Protein assays were done using a DC Protein assay kit (BioRad, Hercules, CA)
using the microplate assay protocol. Working reagent was made up using 20l of
reagent S added to every ml of reagent A needed (A’). Protein standards were made
using bovine albumin at concentrations of 0.25mg/ml to 2mg/ml in order to prepare a
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standard curve. A 5l aliquot of both standards and samples were pipetted into the wells
of a 96-well microtiter plate. Then 25l of reagent A’ was added to each well followed by
200l of reagent B. The plate was gently mixed and allowed to sit at room temperature
for 15 minutes. Absorbances were then read at 750nm using a Synergy H1 Hybrid
Reader (BioTek Instruments, Winooski, VT).
Western Blot
Polyacrylamide SDS gels (separating gel 7.5% and stacking gel 4% acrylamide)
were poured. BioRad Kaleidoscope Precision Plus Protein Standards (BioRad,
Hercules, CA; 12l) were used with each electrophoresis run. Sample protein (protein
amounts as indicated in each figure, 20l) were combined with 5L of 5X sample
diluting buffer (0.3M Tris, 50% glycerol, 5% SDS, 0.5M DTT, and 0.2% Bromophenol
Blue) and boiled in water for five minutes. The gel was then loaded with standard and
samples and electrophoresed at 200V until the dye front exited the gel. The proteins
were then transferred to PVDF transfer membrane (BioRad, Hercules, CA 0.2μM pore
size). Specifically, the membrane was initially soaked in methanol, rinsed in deionized
water, and then placed in transfer buffer (10% 10X electrode buffer, 20% methanol, and
deionized water). Once electrophoresis was complete, the gel was removed and placed
on the aforementioned membrane and filter papers and placed in a transfer apparatus
(Trans-Blot® Cell; BioRad) filled with transfer buffer. A current was run through at
400mAmps for an hour and a half. The gel was carefully removed and excess
membrane was cut away and the lanes were cut out and separated according to the
antibody into which each would be incubated. The membrane was rinsed in PBS 3
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times for five minutes each rinse. The sample containing membrane was then incubated
in a blocking buffer (0.2% I-Block (Applied Biosystems; Foster City, CA), 0.1% Tween20 in 1X PBS, pH 7.4) and placed on a rocker for one hour. The necessary primary
antibody was diluted (per figure legends) in a second blocking buffer (5% NGS, 0.2%
Triton X-100, 0.1% sodium azide in PBS) and the primary antibody was placed on top of
the membrane and left in the refrigerator in a wet chamber overnight. The next day the
membranes were removed from primary antibody and were rocked for 10 minutes each
in two changes of I-block buffer (0.2% I-Block, 0.1% Tween-20, 1X PBS). It was then
removed from the buffer and incubated in a goat anti-rabbit alkaline phosphatase (AP)conjugated secondary antibody (diluted 1:1000 in I-block buffer) for 1 hour. The
secondary antibody was removed and the membranes were washed three times for 15
minutes in I-block buffer. The membrane was then washed twice in assay buffer (0.1%
Tween 20 in TBS). Membranes were then laid down on a plastic block and Immun-Star
AP substrate (BioRad, Hercules, CA) at 37⁰C was applied to the membranes for five
minutes. The substrate solution was then removed and the membranes were blotted
with Kim Wipes before being wrapped in clear plastic wrap. These were taken to a dark
room and developed using a SRX-101A film processor (Konica Minolta, Chiyoda,
Tokyo, Japan). After films were developed, they were scanned into a computer and
ImageJ was used to measure optical densities of each band.
Calpain-Glo Assay
Myotubes were differentiated for four days in horse serum media in 24 well plates
followed by transduction with 200MOI HERG1A or GFP virus (12 wells each). Wells
were then washed with two changes of 37°C PBS. A Calpain-Glo™ Protease Assay kit
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(Promega, Madison, WI) was used to assay calpain activity. The kit included a CalpainGlo Buffer, Suc-LLVY-Glo Calpain Substrate, and Luciferin Detection Reagent which,
when combined, is referred to as Calpain-Glo Reagent. A stock buffer solution of 0.2%
Triton X-100 in PBS and 200nM epoxomicin (BostonBiochem, Cambridge, MA, Cat. #I110) was made in order to permeabilize the cells (Triton) and inhibit the proteasome
(epoxomicin). To begin, 200μl of the 4 separate buffer solutions each containing either
2.0mM EDTA, 2.0mM CaCl2, or buffer alone were added to 6 wells (3 Control, 3 HERG).
These were allowed to sit at room temperature for 5 minutes to ensure the cells were
permeabilized and the proteasome inhibited. After 5 minutes 200μl of the Calpain-Glo
reagent was added to all wells and allowed to sit at room temperature for 15 minutes. A
200μl aliquot of the liquid was removed to a white-walled 96 well plate and
luminescence was read by a Synergy H1 Hybrid Reader (BioTek Instruments, Winooski,
VT). The remaining well contents were scraped from the back of the plate, triturated
using a syringe and 26 gauge needle and then centrifuged to remove solid material.
The supernate was assayed for protein content using the BioRad DC kit (described
above). The protein data were used to normalize the calpain activity.
Statistics
In general, statistics were done using a simple student t-test and SAS (SAS Inc.; Carey,
NC). Results were considered significant when p<0.05.
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CHAPTER 3
RESULTS
Specific Aim I: An in vitro model of HERG1A Overexpression in C2C12 myotubes.
ERG1 Protein Content in Myoblasts and Myotubes. To study the effect of HERG1A
expression on myotubes, we first had to develop an in vitro model overexpressing
HERG1A. This first entailed determining the amount of native MERG1A protein
detectable in both C2C12 myoblasts and 5 day differentiated myotubes. Western blot
revealed a statistically significant 40.7% greater abundance of MERG1A protein in
myotubes than in myoblasts (p<0.01; Figure 8).
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Figure 8. Expression of MERG1A protein is 40.7% higher in myotubes than in
myoblasts. (A) Western blot shows protein levels of MERG1A in undifferentiated
myoblasts and myotubes (50g protein per lane). Protein extracted from mouse brain
was used as a positive control. (B) To show that equal amounts of protein were loaded
into each lane, the membrane was stained for protein with Coomassie blue (G-250;
BioRad, Hercules, CA). (C) The mean optical densities from three samples are shown
here with a bar graph. The bars represent the mean of three samples while with the
error bars revealing the standard error of the mean (mean ± SEM).
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Overexpression of HERG1A in Myotubes. We next wanted to determine to what
extent the HERG1A protein would be overexpressed in response to the transduction of
myotubes with HERG1A virus. Thus, the HERG1A and control adenoviral particles,
both encoding GFP, were transduced into myotubes. The HERG1A treated myotubes
were found to have an increased amount of HERG1A protein while, as expected, the
control myotubes showed no HERG1A protein present. Optical densities were
determined, revealing that there was no difference in MERG1A protein levels between
control and HERG1A-transfected cells (Figure 9).
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Figure 9. HERG1A can be overexpressed in myotubes using viral particles. (A)
HERG1A and MERG1A protein (50g protein each lane) are detected in C2C12
myotubes 48 hours after transduction with HERG1A virus whereas control cells solely
express MERG1A. Protein extracted from mouse brain was used as a positive control
and (B) the membrane was stained for protein using Coomassie blue stain to
demonstrate that equal amounts of protein were loaded into each well. (C) The mean
optical densities from three experiments were plotted as a bar graph. The bars
represented the mean and error bars represented the standard error of the mean (mean
± SEM).
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Overexpression of HERG1A Induces Atrophy in Myotubes. To explore further the
effect of the HERG1A channel on muscle, we transduced myotubes with control and
HERG1A-encoded virus and imaged the cells at 48 and 72 hours post-treatment (Figure
10A). We measured the area of the myotubes and discovered that HERG1A treatment
produced a significant 30.5% and 21.4% decrease in myotube area at 48 and 72 hours
post transduction, respectively (p<0.01) (Figure 10B). At this point, we have ensured
that our viral transduction is successful in penetrating the cell, translating the encoded
protein, and decreasing the size of the cell, thus simulating atrophy in vitro.
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Figure 10. HERG1A expression in C2C12 myotubes induces a decrease in myotube
area. (A) Images of control and HERG expressing myotubes at 48 hours post
transduction. Scale bar = 50

m. (B) Myotube area was determined using ImageJ and

revealed a significant 30.5% decrease in cell size when cells were treated with
HERG1A. Bars representthe mean of three experiments with the standard error of the
mean (mean ± SEM) represented by error bars (left to right n= 69, 63, 81, 78).
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Our results have allowed us to demonstrate that we have a successful in vitro
model of skeletal muscle atrophy resulting from over-expression of the voltage gated
potassium channel HERG1A in C2C12 myotubes. Differentiated myotubes presented
with a greater abundance of MERG1A protein than the undifferentiated myoblasts.
Transduction with an adenovirus coding for HERG1A was shown to successfully
synthesize the HERG1A protein within myotubes and cause a decrease in myotube
area. This data combined allowed us to conclude that we have successfully simulated
atrophy using a HERG1A encoded adenovirus in C2C12 myotubes.
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Specific Aim 2: Investigation of the effect of HERG1A on voltage gated calcium
channels.
Observation of the increase in intracellular calcium resulting from HERG1A
overexpression (Figure 7) led us to question the source of this increased calcium. We
wanted to determine if the calcium was coming from the exterior through sarcolemmal
L-type calcium channels or was it perhaps released from internal stores of calcium.
Because the ERG1A channel is detected in the sarcolemmal membrane, where the
Cav1.1 calcium channels are found in skeletal muscle, we turned our attention to the
voltage gated calcium channel family (i.e., CAV, DHPR), specifically Cav1.1, 1.2, and
1.3, and included the Cav1.1e splice variant found only in the embryonic stage.
HERG1A Overexpression Does Not Affect Expression of Cav1.2 and 1.3. Cav1.1
mRNA levels were not significantly different from controls at 48 hours after transduction
(Figure 11A) which is when we detected an increase in intracellular calcium
concentration (Figure 7). The embryonic splice variant, Cav1.1e, was also examined,
however, no difference in that mRNA level in response to HERG1A was detected
(Figure 11B). Interestingly, we did detect a significant 2.26 fold increase in Cav1.1
mRNA at 72 hours after transduction with the HERG1A virus (Figure 11A); however, the
increase in intracellular calcium concentration was detected prior to this time point. As
expected Cav1.2 and 1.3 were not expressed in the skeletal muscle of mice nor in the
C2C12 cells even after treatment with HERG1A (data not shown).
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Figure 11. Cav1.1 channel mRNA increases in HERG1A treated myotubes at 72 hours
after transduction. (A) Expression of HERG1A in C2C12 myotubes shows a significant
2.3 fold increase in voltage gated calcium channel 1.1 (Cav1.1) gene expression 72
hours post transduction, although there is no significant increase at 48 hours post
transduction when the increase in intracellular calcium concentration is noted. (B) There
was no significant difference in the amount of gene expression of the embryonic voltage
gated calcium channel (Cav1.1e). Gene expression was compared to that of an 18S
positive control. Bars represent means while error bars represent the standard error of
the mean (mean ± SEM; n=3).
In order to support the real time PCR data, an immunoblot was performed on
C2C12 myotubes that were treated with either control or HERG1A virus (Figure 12).
The cells were transduced for 96 hours. Note: This time point is 24 hours past the time
point at which we saw the increase in mRNA which would allow enough time for
transcription and translation of the voltage gated calcium channel to take place. Our
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results show that there was no change in the abundance of protein in the myotubes at
this time, although we saw an increase of mRNA expression through qPCR. We
suspect that the small increase in Cav1.1 transcription detected by qPCR is either not
physiologically significant enough to produce an increase in translation and thus protein
abundance or the difference in protein abundance is not detectable.
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Figure 12. Cav1.1 protein abundance did not change in response to HERG1A
expression in C2C12 myotubes. (A) Immunoblot for the L-type voltage gated calcium
channel Cav1.1 (65g protein per lane). (B) Coomassie blue stain of the PVDF
membrane for protein shows that equal amounts of protein were added to each lane.
(C) No significant difference in the amount of protein was detected in HERG1A treated
cells compared to those of the control cells at 96 hours after transduction with the
HERG1A virus. Bars represent means while error bars represent the standard error of
the mean.
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Specific Aim 3: Investigation of the effects of HERG1A-modulations of calpain activity.
Because HERG1A transduction results in increased intracellular calcium
concentrations (Figure 7; [32]), we next wanted to investigate the downstream effects of
this increase. Specifically, we began by monitoring activity of the calcium-activated
calpain enzymes. Cells were treated with 1mM final concentration of calcium to ensure
that calpain activity could be measured and 1mM EDTA, a calcium chelating agent, was
used to remove calcium from the system to yield a baseline level of non-calcium
activated proteolytic activity. We used a Calpain-Glo assay kit (ProMega; Madison, WI)
to monitor the combined activities of both calpain 1 and 2 and observed a 25.7%
increase in basal calpain activity at 48 hours after transduction with HERG1A encoded
viral particles (Figure 13).
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Figure 13. Calpain activity was increased by a significant 25.7% in HERG1A
treated C2C12 myotubes. The calpain activity in the calcium treated control cells was
19.2% greater than that in the EDTA treated control cells, but the difference was not
statistically significant. Bars represent means and error bars represent standard error
from the mean (mean ± SEM; n=3).
Calpain enzymes are calcium activated and thus the activity will increase with
increased intracellular calcium. However, we cannot assume that the increased calcium
is the only explanation for the increased calpain activity. Other possible causes include:
increases in calpain transcription and/or calpain protein levels or a decrease in
calpastatin (a conventional native calpain inhibitor) transcription and/or its protein levels.
Thus, we asked if calpain and calpastatin transcription levels (i.e., amount of mRNA
produced) changed in response to HERG1A treatment. We used quantitative real time
PCR and revealed that, although HERG1A treatment may produce a potential small
trend of calpain 2 increase over time for 72 hours post viral transduction, it does not
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produce a statistically significant change in calpain 2 gene expression for 84 hours after
viral treatment (Figure 14). Further, no change in gene expression was detected for
calpains 1 or 3 (data not shown).

Figure 14. Expression of HERG1A in C2C12 myotubes did not produce a significant
difference in calpain 2 gene expression. Bars represent means and error bars represent
standard error from mean (mean ± SEM; n=3).
Immunoblots were performed to determine if there was any change in the
amount of calpastatin or specific calpain protein in response to HERG1A treatment. For
calpain 1, the optical densities of both bands in the doublet were measured and the
statistics performed show that there is no difference in calpain 1 protein abundance
(Figure 15).
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Figure 15. Calpain 1 protein abundance was not affected by HERG1A treatment. (A)
Immunoblot of myotube lysates for calpain 1 (60g) reveals that there is no significant
difference in the amount of calpain 1 protein in HERG1A treated myotubes compared to
those of the control at 48 hours after transduction. (B) Coomassie blue stain of PVDF
membrane proteins shows that equal amounts of protein were loaded into each lane.
(C) HERG1A treatment of myotubes did not affect significantly affect calpain 1 protein
abundance. The bars represent the means while error bars representing the standard
error of the mean (mean ± SEM; n=3).
Calpain 2, when autolyzed and hence activated, has been seen to appear as two
separate bands as stated previously. Figure 16 demonstrates this doublet found at
~75Kd. Our results show that there is in fact a 40.69% decrease in calpain 2 (i.e., m41

calpain) in response to HERG1A treatment.

Figure 16. There is a 40.69% decrease in calpain 2 protein abundance in HERG1A
transduced myotubes. (A) Immunoblot for calpain 2 protein (60g per lane). (B) To
show that equal amounts of protein were loaded into each lane, the membrane was
stained for protein with Coomassie blue. (C) HERG treatment resulted in decreased
calpain 2 protein abundance. Bars represent the mean of three samples while error
bars represent the standard error from the mean (mean ± SEM; n=3).
Calpain 3 is a skeletal muscle specific calpain that is not calcium dependent and,
like other calpains, is believed to take part in the degradation of anchoring proteins.
However, it is also suggested that calpain 3 takes part in the remodeling of the
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sarcomere in times of cellular stress. We immunoblotted for calpain 3 protein and
discovered that there is indeed a significant 38.9% decrease in calpain 3 protein
abundance in response to HERG1A treatment (Figure 17).
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Figure 17. There is a significant 38.9% reduction of calpain 3 protein in C2C12
myotubes in response to HERG1A expression. A. Immunoblot of calpain 3 (60g protein
per lane). B. Coomassie blue protein stain of transferred PVDF membrane
demonstrates that equal amounts of protein were added to each well. C. A significant
23.48% reduction of calpain 3 protein was observed. Bars represent the mean of three
samples with error bars representing the standard error from the mean (mean ± SEM;
n=3).
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Calpastatin, as previously, stated is a native inhibitor of conventional calpains.
Therefore, we were interested in investigating the effect of HERG1A treatment on
calpastatin transcription and protein levels. Again using C2C12 myotubes and
quantitative real time PCR, we measured the amount of calpastatin mRNA present in
response to HERG1A treatment. Our findings revealed that there was no significant
change in calpastatin mRNA in response to HERG1A treatment over 84 hours. (Figure
18).

Figure 18. Quantitative PCR shows that there was no significant change in calpastatin
gene expression in response to HERG1A expression. The fold change in calpastatin
mRNA showed no significant difference when compared to the 18S reference gene.
Bars represent the mean and error bars represent the standard error of the mean (mean
± SEM; n=3).
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Immunoblots were done to observe the amount of calpastatin protein. The results
show that there is a significant 37.7% decrease in calpastatin abundance found in the
HERG1A transduced cells as opposed to control cells (Figure 19).

Figure 19. Calpastatin protein abundance was decreased by a significant 37.72% in
myotubes treated with HERG1A. A. Immunoblot of control and HERG1A treated
myotubes (60g protein per lane). B. Coomassie blue protein stain of transferred PVDF
membrane demonstrates that equal amounts of protein were added to each well. C.
Calpastatin protein abundance decreases in response to HERG1A. Bars represent the
mean of three samples while error bars represent the standard error from the mean
(mean ± SEM; n=3).
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CHAPTER 4
DISCUSSION
The ERG1a voltage-gated K+ channel is responsible for late repolarization of the
cardiac action potential and was thought to be absent from skeletal muscle [23, 35],
however, the Pond and Hannon labs demonstrated that this protein is detectable in
atrophying skeletal muscle [24]. Consequent studies have shown that ERG1a
expression leads to an increase in the E3 ubiquitin ligase MURF1 and contributes to
activation of the ubiquitin proteasome proteolysis known to contribute to skeletal muscle
atrophy [24, 25]. A new study has now shown that ERG1a expression also increases
the amount of [Ca2+]i in C2C12 myotubes (unpublished data, Pratt, Hockerman, Pond
2018) (Figure 6). However, the source and downstream effects of the calcium increase
have yet to be investigated. Here we have initiated these studies.
We have shown that HERG1A increases intracellular calcium in C2C12
myotubes. There are numerous mechanisms by which this could occur. For example
the IP3 pathway, in which a G coupled receptor (GPCR) activates phospholipase C
(PLC), which in turn cleaves phosphatidylinositol 4, 5 bisphosphate (PIP 2) into IP3 and
diacylglycerol (DAG). The IP3 binds to its receptor, IP3R, yielding a release of calcium
from its internal SR stores into the cytoplasm. Therefore, any changes in IP3 levels can
change the amount of intracellular calcium, because of release from the SR [36].
Another protein known as smooth endoplasmic reticular calcium ATPase (SERCA) is
found within the SR membrane and is responsible for transporting calcium back into the
SR. Decreases in SERCA activity could reduce the return of calcium to internal stores,
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thus allowing a buildup of [Ca2+]i in the cytoplasm and a reduction in Ca2+ concentration
within the SR [36]. Lastly, the focus of this study are the Cav1.1 channels which are
found along the sarcolemmal membrane and also in t-tubules. Changes in voltage along
the t-tubules allows for a conformational change that affects ryanodine receptors within
the SR allowing for calcium release, this in turn leads to excitation contraction coupling
(ECC). Any changes in the Cav1.1 channel abundance or activity may lead to changes
in the release of calcium from the SR [36]. Because ERG1a is a membrane bound
protein detected on cardiac t-tubules [21, 37] and in the I-band of skeletal muscle where
t-tubules are located (unpublished data, Zampieri and Pond), we thought it would be
possible for ERG1a to have an effect on the L-type voltage-gated calcium channel
Cav1.1. Cav1.1 is specific to the skeletal muscle membrane and is accepted to be the
voltage sensor for excitation contraction coupling (ECC) in this tissue. Cav1.2 and 1.3
have not been reported in skeletal muscle, but are detected in cardiac muscle and
adrenal glands, respectively. Cav1.1 works by sensing an action potential that moves
down the t-tubules. Once this action potential is recognized, the Cav1.1 channel
undergoes a conformational change which allows it to interact physically with the
ryanodine receptors to release calcium from stores in the sarcoplasmic reticulum [28,
30, 38, 39]. This calcium release initiates ECC. Once ECC has occurred, reuptake of
calcium into the SR occurs SERCA [38]. In a 2016 study by Sultana and colleagues
reported that during maturation an embryological Cav1.1 splice variant, that excludes
exon 29 of Cav1.1 (Cav1.1e), was found. After maturation this splice variant is replaced
by an adult splice variant that includes exon 29 [28, 40]. It is suggested that the
embryological splice variant differs from the adult in that it is much more sensitive to
48

voltage changes and spends an increased amount of time in the “open” state. Because
it remains in the open state longer, Cav1.1e conducts much larger calcium currents as
opposed to its adult counterpart. This small change in the channel’s structure allows
calcium to be better regulated in adult muscle as opposed to developing muscle [40].
However, skeletal muscle is always adapting to demand and the Sultana study noted
that knockout of Cav1.1e appeared to have effects on skeletal muscle similar to that of
endurance training. Further investigation revealed Cav1.1e affected muscle fiber type
composition in mice, causing an increase in slow type muscle fibers. Consequences of
this change include: reduced tetanic, maximal twitch and grip force. Additionally,
Cav1.1e and its increase in calcium flux appears to cause mitochondrial damage [34].
For this reason it is reasonable for us to hypothesize that Cav1.1 or its variant may
produce an increase of calcium from internal stores. However, our investigation
revealed that neither the Cav1.1 nor the Cav1.1e channel is affected by the presence of
ERG1a. However, it is still possible that ERG1a affects Cav1.1 channel kinetics. This
study is beyond the scope of this project and will be conducted in collaboration with a
lab that focuses on electrophysiology.
Another possibility is that ERG1a affects calcium levels by modulation of IP3. A
previous study done by Perez-Neut [32] used a HERG activator (NS1643) on SkBr3
breast cancer cells and found that indeed HERG activation leads to an increase in
[Ca2+]i which promotes UPP activation and degradation of the cell cycle regulator
protein, cyclin E2. Furthermore, activation of HERG via NS1643 hyperpolarized the
membrane potential of the SkBr3 cells which are otherwise non-excitable. Their report
suggested that hyperpolarization may perhaps increase intracellular negative charge
49

leading to the entry of positively charged calcium into the cells. By blocking voltage
gated calcium channels using CoCl2 and activating HERG, a large increase in [Ca2+]i
was discovered, these results suggested to them that the calcium entry was not a result
of voltage gated calcium channel activity. Instead, they hypothesized that the inositol
signaling pathway (IP3) may have some effect on calcium entry. This data along with
our own suggest that the Cav1.1 channel is not involved with this increase in [Ca2+]i.
Indeed, our lab now has preliminary data which suggests that intracellular calcium
stores are involved in the increased [Ca2+]i (unpublished data, Pratt, Hockerman and
Pond).
We were also able to demonstrate that in the presence of HERG1A, myotubes
had an increased amount of calpain activity. At this time it is not possible to discern if
calpains 1 and 2 are modulated differently and, if so, how. That is, is one of these
isoforms transcribed or translated more than the other? Or is one activated more so
than the other as a result of different effects on localized calcium concentration? The
calpain system is complicated, and the activation of calpains is disputed. One thing that
is agreed upon is that calpains must be autocatalyzed in order to be activated,
specifically, on the N terminus [13, 16, 41, 42]. Indeed, the autolysis can be noted in our
immunoblots (Figure 13-15) where multiple bands are seen [43]. The largest amount of
controversy however concerns how calpains are activated. Calpain 1 has been shown
to be at half maximal activity at low Ca2+ concentration (3-50 µM) while Calpain 2
reaches half maximal activity at higher concentrations (400-800 µM). Taken together,
our lab’s unpublished data showing that HERG1A expression in C2C12 myotubes yields
an increase in [Ca2+]i combined with the results reported here which show that HERG1A
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expression produces increased calpain activity, suggest that HERG1A is increasing
calpain activity by increasing intracellular calcium concentration. However, it is possible
that there is an increased abundance of calpain 1 and/or calpain 2 protein(s) or that
there is a decrease in the abundance of the native calpain inhibitor calpastatin.
Calpains 1 and 2 are known as “conventional” calpains and are found throughout
the body. Here we report a decrease in calpain 2 protein abundance in C2C12
myotubes in response to HERG1A expression while calpain 1 shows no detectable
change in protein abundance. These data are aligned with the quantitative PCR data
which demonstrate that there is no change in transcription of calpain 1 or 2 genes.
Indeed, one would expect there to be no increase in calpain proteins without an
increase in gene expression, although there could still be an increase in the protein as a
result of decreased proteolysis. Because we see a decrease in calpain 2 without a
change in transcription of that gene, we can speculate that the calpain 2 protein may be
undergoing an increased level of degradation. Is it possible that the HERG1A protein is
increasing ubiquitin proteasome proteolysis of calpain 2?
Calpains 1 and 2 are known to be upregulated during skeletal muscle atrophy
caused by hind limb suspension, in a 2015 article by Shenkman and colleagues they
inhibited calpain activity using the calpain inhibitor PD150606 [44]. Their results
demonstrated that blocking calpain activity reduced the activation of calpain 1 gene
expression and attenuated skeletal muscle atrophy. Mafbx/ATROGIN expression was
also decreased in their experiments, however, there was no change in MURF1
expression, suggesting that although calpains affect Mafbx gene expression they have
no effect on Murf1. In 2006, Fareed and colleagues [7] reported that calpain inhibition
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also deterred muscle proteolysis induced by sepsis, however, they reported that this
was independent of Mafbx and Murf1/ATROGIN gene expression. Interestingly, the
Pond and Hannon labs showed that Merg1a expression in mouse skeletal muscle
increased Murf1 transcription and translation, but not that of Mafbx/ATROGIN [25]. The
data suggest that ERG1A indeed has an effect on expression of UPP components, but
does not suggest any connection with calcium up-regulation or increased calpain
activity. Indeed, we find no report describing any calcium dependence by the UPP.
Indeed, calpains are known to degrade skeletal muscle anchor proteins (e.g., titin, actinin, etc.) and, thereby release contractile proteins (i.e., actin and myosin) which are
then degraded by the UPP [15, 45, 46]. We suggest that ERG1a may participate in the
coordination of this effort by affecting both UPP and calpain activities.
Our results have shown that not only does calpain 2 protein abundance
decrease, but calpain 3 protein abundance decreases as well. Calpain 3 is skeletal
muscle specific and the absence or reduction of this protein leads to limb-girdle
muscular dystrophy type 2A (LGMD2A) in humans [13, 41, 42, 47-50]. It is also
interesting in that its regulation is not controlled solely by calcium but also by sodium
concentrations; however, the physiological relevance of this discovery is debated [42,
51]. In vitro it has been shown that the Ca2+ concentration needed for calpain 3 to
become completely active (in the absence of sodium) is 0.1mM. Whereas in the
absence of calcium the Na+ concentration needed is much larger for activation, being
100mM. However, when both ions are present they act together and decrease the
concentration needed for either ion for calpain activation [37]. In vivo experiments have
been done to observe the Ca2+ concentration that is necessary to cause autolysis
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(activation) in skeletal muscle tissue. The findings concluded that increased levels of
calcium (200nM) were sufficient to autolyze ~20% of endogenous calpain 3 in a resting
muscle fiber. The calpain activity, however, was dependent on the exposure duration
and the presence of ATP. If the Ca2+ concentration became high enough, then ATP was
not needed. It appears that the ATP increased the calpain 3 sensitivity to Ca2+ [49, 50].
It has been suggested, using calpain 3 knock out mice, that calpain 3 acts upstream of
the UPP, although it is uncertain if calpain 3 directly cleaves proteins to make them
accessible for ubiquitination [47]. What makes calpain 3 interesting is that it is not only
known to break down proteins, but also takes part in remodeling of the sarcomere in
response to cellular damage such as atrophy [42, 47]. It is proposed that calpain 3 is
actually localized to the myofibrillar structure. In vitro it has been reported that calpain 3
targets include Z-disk proteins such as titin, filamin C, talin, and myosin light chain 1.
This is supportive of a role for calpains in sarcomeric remodeling in response to cellular
damage. In a report by Murphy and colleagues [41] they found that in response to
eccentric exercise calpain 3 is autolyzed (activated). This would mean that calpain 3 is
responding to the accumulation of minor damage to the sarcomere resulting from
exercise by remodeling/repairing the structure; this occurrence is absent from those with
LGMD2A. In a second report in 2010 Murphy [46] mentions that calpain 3 is not
detected until later in development, following myoblast proliferation and fusion, this
could explain why LGMD2A is a late onset disease (20-40 years of age), accumulated
damage is not repaired due to the absence of calpain 3, leading to muscle wasting.
Evidence has shown that the absence of calpain 3 may lead to a reduction in protein
turnover and cause the accumulation of proteins that are damaged or misfolded. An
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increase in misfolded and damaged proteins can lead to cellular stress. Indeed, studies
have revealed an increase in heat shock proteins in response to the absence of calpain
3. This in turn may lead to cellular stress and toxicity, thus leading to muscle pathology
(i.e., atrophy, dystrophy) [47, 52].
Calpastatin is a native calpain inhibitor which assists in maintaining calpain
activity by inhibiting conventional calpains 1 and 2, but not calpain 3. A decrease in
calpastatin protein decreases the ability of calpains to be regulated by inhibition.
Calpastatin requires calcium in order to bind to calpains, but the concentration that is
required is dependent on the calpain type [15]. When calcium concentrations rise,
calpain activity is increased, thus calpastatin is needed to regulate their activity [13]. In
our investigation of calpastatin the decrease in its protein abundance correlates with our
calpain activity results. That is, in the absence of calpastatin, it would be expected to
see an increase in calpain activity because it is no longer being inhibited by calpastatin.
In summary, our results suggest that voltage gated calcium channels are in fact
not the cause of HERG1A-modulated increases in [Ca2+]i. It is possible, therefore, that
[Ca2+]i is affected by a different mechanism such as a change in IP3 abundance or the
ability of SERCA to reuptake calcium into the SR. We also provide evidence that
ERG1a increases calpain activity in myotubes, likely resulting from the increase in
[Ca2+]i. Our observations of decreased calpain 2 and 3 abundance could be a result of
their degradation, perhaps resulting from a feedback loop to decrease proteolysis
despite or because of the increased calcium concentration. The decrease in calpain 3
may also be related to a decreased ability to remodel the sarcomere after atrophy,
however, this possibility would require much additional investigation. Furthermore, the
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decrease in calpastatin protein abundance may contribute to the increase in calpain
activity that may also result from increased calcium concentration. Overall, our results
suggest that HERG1A modulates intracellular calcium and calpain activity. Indeed, its
interaction with calcium and calpains may work upstream of the UPP, and indeed
modulate the UPP, having a multi-faceted modulatory effect on skeletal muscle atrophy.
Indeed, ERG1a will likely never be a target for pharmacological treatments of atrophy,
however, continuing study of this protein may reveal other possible targets to combat
atrophy.
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